[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastric-and-gastroesophageal-junction-gej-adenocarcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastric-and-gastroesophageal-junction-gej-adenocarcinoma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100594735","phase-3-a-phase-iii-clinical-study-of-cadonilimab-plus-sox-as-perioperative-treatment-for-patients-with-resectable-ggej-adenocarcinoma-100594735",false,"NCT07023315","A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G\u002FGEJ Adenocarcinoma","A Randomized, Double-blind, Phase III Clinical Study Comparing the Efficacy and Safety of Cadonilimab Plus Oxaliplatin and Tegafur-Gimeracil-Oteracil Potassium (SOX) Versus Placebo Plus SOX as Perioperative Treatment for Patients With Resectable Gastric and Gastroesophageal Junction (G\u002FGEJ) Adenocarcinoma","Inclusion Criteria:\n\n1. Patients with histologically confirmed gastric or gastroesophageal junction adenocarcinoma with resectable disease (clinical stage T3-4aN+M0 or T4bNanyM0 per AJCC 8th edition).\n2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrollment.\n3. Has life expectancy of at least 6 months.\n4. Availability of tumor sample prior to study entry.\n5. Patients must undergo radical surgery.\n6. Has adequate organ function.\n\nExclusion Criteria:\n\n1. Patients with unresectable locally advanced disease or distant metastasis.\n2. Histopathology or cytology confirmed other pathological types, such as adenosquamous cell carcinoma, squamous cell carcinoma, or GI stromal tumor.\n3. Current or prior use of immunosuppressive medication within 14 days before randomization.\n4. Has received prior anti-cancer therapy for the current malignancy.\n5. Has an active infection requiring systemic therapy.\n6. Contra-indication to any of the study drugs.\n7. Has a known additional malignancy that is progressing or has required active treatment within the past 5 years.\n8. Has an active autoimmune disease that has required systemic treatment in past 2 years.\n9. Known active Hepatitis B or Hepatitis C virus infection.\n10. Has had an allogenic tissue\u002Fsolid organ transplant.","ALL","18 Years","75 Years",{"count":20,"type":21},760,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This study investigates treatment of cadonilimab or placebo combined with SOX chemotherapy (oxaliplatin + tegafur-gimeracil-oteracil potassium) given before surgery (neoadjuvant) and cadonilimab or placebo combined with SOX chemotherapy after surgery (adjuvant), will work and be safe for the treatment of resectable (removable by surgery) gastric or gastroesophageal cancer.",[27],"Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma","RECRUITING","2026-02-09",{"date":31,"type":32},"2026-02-11","ACTUAL",{"date":34,"type":32},"2025-08-14",{"date":36,"type":21},"2031-07",{"name":38,"class":39},"Akeso","INDUSTRY",6,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":59,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100562610","pan-tumor-mrd-study-100562610","NCT06605404","Pan-tumor MRD Study","Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers","Eligibility Criteria:\n\n1. Age 18 years or older.\n2. Confirmed histological or cytological diagnosis of a malignant solid tumor that is either specified in one of the pre-defined tumor cohorts or meets the enrollment criteria for the Mix of Solid Tumors (MOST) cohort (Table 1).\n3. Eligible for curative intent therapy, with surgical resection of cancer planned.\n\n   a. If surgical resection has occurred, enrollment should occur within 3 months of surgical resection and before initiation of adjuvant therapy.\n4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2.\n5. No systemic therapy for current cancer diagnosis administered before enrollment.\n6. Willing and able to comply with required study procedures, including blood sample collection and primary tumor tissue submission from diagnostic biopsy or surgical excision.\n7. Has completed all therapy (including endocrine therapy) 3 or more years ago for any previous invasive solid organ malignancy (with exception of nonmelanoma skin cancers) or hematologic malignancy. Individuals with a prior history of noninvasive (in situ) carcinomas may participate if they have received definitive treatment (no washout period required).\n8. No concurrent diagnosis of another invasive cancer, except for nonmelanoma skin cancers.\n9. No prior allogeneic hematopoietic stem cell transplant.\n10. Able and willing to provide informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for the release of personal health information.\n\n    Cohort Specific Criteria\n11. Muscle-invasive urothelial carcinoma of the bladder and Melanoma Cohorts: Stage II or operable III cancer:\n12. Esophageal, Gastric\u002FGEJ, and NSCLC Cohorts: Stage I, II, or operable III cancer.\n13. Pancreatic Cohort: Stage I, II or operable III cancer, exocrine only disease.\n14. MOST cohort: Stage II or operable stage III solid tumor diagnosis that meets eligibility criteria and is not included in the other cohorts.\n\nThe following tumor types are excluded:\n\n1. Central nervous system (CNS) malignancies\n2. Colorectal cancer\n3. Breast cancer\n4. Squamous cell skin cancer\n5. Basal cell carcinoma\n6. Gastrointestinal stromal tumors (GIST)\n7. Thyroid cancer\n8. Uveal melanoma\n9. Low or intermediate grade neuroendocrine tumors\n\n   ■ Eligible tumor types: High-grade neuroendocrine tumors, including neuroendocrine carcinomas, Merkel cell carcinomas, and small cell lung cancer are permissible\n10. Hematologic cancers including multiple myeloma or other plasma cell dyscrasias, Hodgkin\\'s lymphoma, non-Hodgkin\\'s lymphoma, acute or chronic leukemias including chronic lymphocytic leukemia \u002F small lymphocytic leukemia",{"count":49,"type":21},1350,"OBSERVATIONAL","The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to develop tests to better understand cancer, for example, to improve cancer detection and to assess the risk of cancer coming back.\n\nParticipants will receive routine standard of care from their doctor and their involvement is expected to last for approximately five and a half (5.5) years.",[53,54,27,55,56,57,58],"Muscle Invasive Bladder Urothelial Carcinoma","Esophageal Cancer","Melanoma (Skin Cancer)","NSCLC (Non-small Cell Lung Cancer)","Pancreatic (Exocrine Only)","Mix of Solid Tumors (MOST)",[60,61,62],"observational","biospecimen","routine care","2025-08-13",{"date":34,"type":32},{"date":66,"type":32},"2025-01-08",{"date":68,"type":21},"2032-04",{"name":70,"class":39},"Paradigm Health",2,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":95},"100594953","phase-2-perioperative-treatment-of-combined-radiotherapy-with-sox-apatinib-and-camrelizumab-for-oesophagogastric-cancer-100594953","NCT07026149","Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer","Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Resectable Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma: A Phase II Trial","Inclusion Criteria:\n\n* Has previously untreated localized gastric or GEJ adenocarcinoma as defined by T3-4N+M0;\n* Plans to proceed to surgery following pre-operative chemotherapy. Has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.\n* Has adequate organ function.\n* Male participants of childbearing potential must agree to use an adequate method of contraception for the course of the study through 120 days after the last dose of therapy.\n* Female participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of therapy.\n* Has life expectancy of greater than 12 months.\n\nExclusion Criteria:\n\n* Uncontrolled hypertension ( systolic ≥140 mmHg or diastolic ≥90 mmHg despite antihypertensive therapy)\n* Known hypersensitivity to any of the study drugs or excipients.\n* Known hereditary or acquired bleeding and thrombotic tendencies (e.g. hemophiliacs, coagulation disorders, thrombocytopenia, etc.);\n* Congenital or acquired immune deficiency (e.g. HIV infected)",{"count":80,"type":21},30,[82],"PHASE2","The study is being conducted to evaluate the efficacy, safety and tolerability of radiotherapy and chemotherapy, apatinib with camrelizumab in the neoadjuvant (prior to surgery) and adjuvant (after surgery) treatment of previously untreated adults with gastric and gastroesophageal junction (GEJ) adenocarcinoma.",[27],"2025-06-10",{"date":87,"type":32},"2025-06-18",{"date":89,"type":21},"2025-06-08",{"date":91,"type":21},"2030-05-31",{"name":93,"class":94},"Ruijin Hospital","OTHER",1]